Cargando…

Clinical biomarkers for Lewy body diseases

Synucleinopathies are a group of neurodegenerative disorders characterized by pathologic aggregates of neural and glial α-synuclein (α-syn) in the form of Lewy bodies (LBs), Lewy neurites, and cytoplasmic inclusions in both neurons and glia. Two major classes of synucleinopathies are LB disease and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelmoaty, Mai M., Lu, Eugene, Kadry, Rana, Foster, Emma G., Bhattarai, Shaurav, Mosley, R. Lee, Gendelman, Howard E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644566/ https://www.ncbi.nlm.nih.gov/pubmed/37964309 http://dx.doi.org/10.1186/s13578-023-01152-x

Ejemplares similares

Immune senescence in aged APP/PS1 mice
por: Abdelmoaty, Mai M., et al.
Publicado: (2023)

Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease
por: Abdelmoaty, Mai M., et al.
Publicado: (2022)

An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
por: Olson, Katherine E., et al.
Publicado: (2023)

Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease
por: Olson, Katherine E., et al.
Publicado: (2021)

Lewy body disease or diseases with Lewy bodies?
por: Menšíková, Kateřina, et al.
Publicado: (2022)

Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)

Matters Arising ‘Lewy body disease or diseases with Lewy bodies?’
por: Jellinger, Kurt A.
Publicado: (2022)

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
por: Leyhe, Thomas, et al.
Publicado: (2013)

Neurophysiological biomarkers for Lewy body dementias
por: Cromarty, Ruth A., et al.
Publicado: (2016)

Reply: Matters Arising ‘Lewy body disease or diseases with Lewy bodies?’
por: Menšíková, Kateřina, et al.
Publicado: (2022)

Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease
por: Bousiges, Olivier, et al.
Publicado: (2022)

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
por: Mukaetova-Ladinska, Elizabeta B., et al.
Publicado: (2010)

Neuroimaging, Biomarkers, and Management of Dementia with Lewy Bodies
por: Hanagasi, Hasmet A., et al.
Publicado: (2013)

Biomarkers in biological fluids for dementia with Lewy bodies
por: Schade, Sebastian, et al.
Publicado: (2014)

CD4+ effector T cells accelerate Alzheimer’s disease in mice
por: Machhi, Jatin, et al.
Publicado: (2021)

Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease
por: Schutt, Charles R., et al.
Publicado: (2018)

Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score
por: Galvin, James E.
Publicado: (2015)

Clinical prevalence of Lewy body dementia
por: Kane, Joseph P. M., et al.
Publicado: (2018)

Clinical diagnosis of Lewy body dementia
por: Surendranathan, Ajenthan, et al.
Publicado: (2020)

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies
por: Foska, Aikaterini, et al.
Publicado: (2022)

Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease
por: Su, Bo, et al.
Publicado: (2009)

Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions
por: Abdelmoaty, Mai M., et al.
Publicado: (2021)

Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders
por: Ho, Gilbert J., et al.
Publicado: (2011)

α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies
por: Kasuga, Kensaku, et al.
Publicado: (2012)

Molecular Pathology of Lewy Body Diseases
por: Beyer, Katrin, et al.
Publicado: (2009)

Parkin Disease and the Lewy Body Conundrum
por: Doherty, Karen M, et al.
Publicado: (2013)

α-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice
por: Uemura, Norihito, et al.
Publicado: (2023)

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
por: Pagan, Fernando, et al.
Publicado: (2016)

Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
por: Scott, Gregory D., et al.
Publicado: (2022)

Fabry Disease With Concomitant Lewy Body Disease
por: Del Tredici, Kelly, et al.
Publicado: (2020)

Therapeutic Strategies for Immune Transformation in Parkinson’s Disease
por: Saleh, Maamoon, et al.
Publicado: (2022)

Clinical characteristics of Lewy body dementia in Chinese memory clinics
por: Gan, Jinghuan, et al.
Publicado: (2021)

Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies
por: Sohma, Hitoshi, et al.
Publicado: (2013)

Biomarkers for the diagnosis of Alzheimer’s disease, dementia Lewy body, frontotemporal dementia and vascular dementia
por: Maclin, Joshua Marvin Anthony, et al.
Publicado: (2019)

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
por: Pereira, Joana B., et al.
Publicado: (2023)

Dementia with Lewy bodies
por: McKeith, Ian
Publicado: (2004)

Lewy body constipation
por: Sakakibara, Ryuji, et al.
Publicado: (2019)

Structural connectivity networks in Alzheimer’s disease and Lewy body disease
por: Baik, Kyoungwon, et al.
Publicado: (2021)

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
por: Gibson, Lucy L., et al.
Publicado: (2023)

Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies
por: Schumacher, Julia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_42m77ctvmlcg1dfpnotlvtpgtn